Rifampicin/isoniazid/pyrazinamide
Combination of | |
---|---|
Rifampicin | Rifamycin antibiotic |
Isoniazid | Anti-tuberculosis medication |
Pyrazinamide | Anti-tuberculosis medication |
Names | |
Trade names | Rifater, Trifazid, others |
Clinical data | |
Pregnancy category |
|
Routes of use | By mouth |
Defined daily dose | not established[1] |
External links | |
AHFS/Drugs.com | FDA Professional Drug Information |
Legal | |
License data | |
Legal status |
|
Rifampicin/isoniazid/pyrazinamide, also known as rifampin/isoniazid/pyrazinamide, is a medication used to treat tuberculosis.[2] It is a fixed dose combination of rifampicin, isoniazid, and pyrazinamide.[2] It is used either by itself or along with other antituberculosis medication.[2] It is taken by mouth.[2]
Side effects are those of the underlying medications.[2] These may include poor coordination, loss of appetite, nausea, joint pain, feeling tired, and numbness.[3] Severe side effects include liver problems.[4] Use in those under the age of 15 may not be appropriate.[4] It is unclear if use in pregnancy is safe for the baby.[4]
Rifampicin/isoniazid/pyrazinamide was approved for medical use in the United States in 1994.[4] It is on the World Health Organization's List of Essential Medicines.[5] The wholesale cost in the developing world is about US$3.93 a month.[6] In the United Kingdom a month of treatment costs the NHS about 39.51 pounds.[7]
Medical uses
The hope of a fixed-dose combination pill is to increase the likelihood that people will take all of three medications.[8] Also, if people forget to take one or two of their drugs, they might not then develop resistance to the remaining drugs.
Dosage
The defined daily dose is not established.[1]
Society and culture
It is manufactured by Aventis.[citation needed]
See also
References
- ↑ 1.0 1.1 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 2 August 2020. Retrieved 18 September 2020.
- ↑ 2.0 2.1 2.2 2.3 2.4 World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 143. hdl:10665/44053. ISBN 9789241547659.
- ↑ "Rifater Side Effects in Detail - Drugs.com". www.drugs.com. Archived from the original on 21 December 2016. Retrieved 18 December 2016.
- ↑ 4.0 4.1 4.2 4.3 "Rifater - FDA prescribing information, side effects and uses". www.drugs.com. October 2016. Archived from the original on 21 December 2016. Retrieved 18 December 2016.
- ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ↑ "Rifampicin + Isoniazid + Pyrazinamide". International Drug Price Indicator Guide. Archived from the original on 19 January 2019. Retrieved 8 December 2016.
- ↑ British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 403. ISBN 9780857111562.
- ↑ Brown, Morris J.; Sharma, Pankaj; Bennett, Peter N. (30 July 2012). Clinical Pharmacology. Elsevier Health Sciences. p. 204. ISBN 978-0-7020-5113-5. Archived from the original on 29 August 2021. Retrieved 7 August 2020.
External links
Identifiers: |
---|
- Pages using duplicate arguments in template calls
- Use dmy dates from September 2019
- Articles with invalid date parameter in template
- Drugs with non-standard legal status
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs that are a combination of chemicals
- All articles with unsourced statements
- Articles with unsourced statements from September 2019
- Chemicals that do not have a ChemSpider ID assigned
- Anti-tuberculosis drugs
- Combination drugs
- Rifamycin antibiotics
- Sanofi
- World Health Organization essential medicines
- All stub articles
- Antiinfective agent stubs